DOST allots P89M for vaccine trial

/ 05:38 AM September 17, 2020

The Department of Science and Technology (DOST) has allotted P89.1 million for the World Health Organization (WHO) Solidarity Trials for Vaccines, expected to start in the third week of October, Health Undersecretary Maria Rosario Vergeire said on Wednesday.

The funds would cover the operational expenses for the trials that would last for 18 months, Vergeire said.


In talks for supplies

The WHO will provide the country with the vaccines, she said.

At least 34 candidate vaccines for COVID-19 are under study for inclusion in the trials.


Seven of the candidates, now in Phase 3 trials, are made by pharmaceutical companies that the Philippine government is in talks for supplies.

The companies are Oxford Astrazeneca, Gamaleya Research Institute, Sinovac, Sinopharm Wuhan, Sinopharm Beijing, BioNtech/Fosun Pharma/Pfizer and Moderna/NIAID.

Vergeire said the DOH was waiting for the WHO’s third shipment of remdesivir, an antiviral under study as a potential treatment for COVID-19.

She said the country was expecting a thousand vials of remdesivir. —JOVIC YEE

For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link .

Subscribe to the Inquirer COVID-19 Newsletter
Read Next
Don't miss out on the latest news and information.
View comments

Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer & other 70+ titles, share up to 5 gadgets, listen to the news, download as early as 4am & share articles on social media. Call 896 6000.

TAGS: coronavirus pandemic, coronavirus Philippines, COVID-19 Vaccine, DOST
For feedback, complaints, or inquiries, contact us.

© Copyright 1997-2020 INQUIRER.net | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.